Design Therapeutics (DSGN) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Lexicon Pharmaceuticals (LXRX) over the past year, gaining 65.6% versus a gain of 23.1%. Over five years, DSGN leads with a -19.4% price change compared with -71.4% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($783.1 million vs $719.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | LXRX |
|---|---|---|
| Share price | $11.49 | $1.76 |
| Market cap | $719.06M | $783.12M |
| 1-day change | -1.71% | 0.00% |
| YTD return | +22.49% | +53.04% |
| 1-year return | +65.56% | +23.08% |
| 5-year return | -19.37% | -71.43% |
| EPS (TTM) | $-1.18 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $2.68 |
| 52-week low | $5.28 | $1.10 |
| Distance from 52-week high | -33.39% | -34.33% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +88.95% | +158.52% |
| Average volume | 604.06K | 2.90M |
| Shares outstanding | 62.58M | 444.96M |
| Employees | 55 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed LXRX by 42.5 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
DSGN vs LXRX FAQ
Which is bigger, Design Therapeutics or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $783.12M compared with $719.06M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, DSGN or LXRX?
DSGN returned +65.56% over the past 12 months, compared with +23.08% for LXRX (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.